Scarica l'app Stockscreener
1.16
4.92%
-0.06
Dopo l'orario di chiusura:
1.19
0.03
+2.59%
Actinium Pharmaceuticals Inc Borsa (ATNM) Ultime notizie
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Barclays PLC Buys 32,784 Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Actinium Pharmaceuticals (ATNM) Stock Price, News & Analysis - MarketBeat
Jane Street Group LLC Sells 24,392 Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Geode Capital Management LLC Has $1.29 Million Stock Holdings in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Actinium Pharmaceuticals Announces Executive Appointments - Marketscreener.com
Actinium Pharmaceuticals, Inc. Appoints Richard Stone to Scientific Advisory Board - Marketscreener.com
Actinium Pharmaceuticals, Inc. Announces Executive Appointments - Marketscreener.com
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
What Awaits Actinium In Q4? - RTTNews
Actinium Pharmaceuticals, Inc. Appoints Robert N. Daly as Vice President, Head of Clinical Operations - Marketscreener.com
Wellington Management Group LLP Acquires Shares of 59,608 Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Charles Schwab Investment Management Inc. Has $136,000 Stock Position in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Targeted Alpha Therapy Market, Drugs Approval, Proprietary Technologies & Clinical Trials: 20+ Drugs of Targeted Alpha Therapy In Clinical Trials - GlobeNewswire Inc.
ATNM stock touches 52-week low at $1.17 amid market challenges - Investing.com Australia
My Top 2 Stock Picks For A 2025 Rebound - Seeking Alpha
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Actinium stock plunges to 52-week low at $1.33 amid market challenges - Investing.com
Actinium Pharmaceuticals 2024 Stockholder Meeting Outcomes - TipRanks
Stephens Reaffirms “Overweight” Rating for Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Actinium Pharmaceuticals Continues R&D Focus Amid Financial Progress - TipRanks
Actinium Pharma keeps stock target with Buy rating on Q3 earnings - Investing.com UK
Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024 - PR Newswire
Actinium Pharmaceuticals Reports $78.6M Cash Position, FDA Trial Clearances in Q3 - StockTitan
HC Wainwright Reaffirms “Buy” Rating for Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Actinium: Q3 Earnings Snapshot - mySA
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives $11.40 Consensus Price Target from Analysts - Defense World
Actinium Pharmaceuticals Inc (ATNM) Quarterly 10-Q Report - Quartz
Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Actinium Pharmaceuticals (NYSE:ATNM) Cut to Sell at StockNews.com - Defense World
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Vanguard Group's Recent Acquisition in Actinium Pharmaceuticals - GuruFocus.com
Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors - PR Newswire
Actinium Pharmaceuticals Appoints June Almenoff to its Board of Directors - citybiz
Adlai Nortye (NASDAQ:ANL) & Actinium Pharmaceuticals (NYSE:ATNM) Financial Comparison - Defense World
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates - MSN
The Manufacturers Life Insurance Company Invests $92,000 in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy - Yahoo Finance
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur - The Manila Times
Hodgkin's Lymphoma Market Size, Share, Growth Insights - openPR
Renaissance Technologies LLC Invests $142,000 in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Actinium Pharmaceuticals (NYSE:ATNM) Lifted to Hold at StockNews.com - Defense World
Comparing Actinium Pharmaceuticals (ATNM) and Its Competitors - Defense World
Radiopharmaceuticals Market Report, Size, Share, Growth, Trends, Industry Analysis, Forecast to 2033 - WhaTech
S&P 500 Down Over 100 Points; Actinium Pharmaceuticals Shares Plunge - MSN
Wall Street SWOT: Actinium stock rides wave of targeted therapy innovation - Investing.com
Comparing ARS Pharmaceuticals (NASDAQ:SPRY) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc.ATNM - PR Newswire
Actinium Pharmaceuticals (ATNM) vs. Its Rivals Head to Head Comparison - Defense World
Bank of New York Mellon Corp Increases Position in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Actinium Pharmaceuticals reports data from Phase III trial of AML treatment - Clinical Trials Arena
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):